{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:52Z","timestamp":1789194472002,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00259-024-06863-y","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:02:33Z","timestamp":1725508953000},"page":"291-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The LUTADOSE trial: tumour dosimetry after the first administration predicts progression free survival in gastro-entero-pancreatic neuroendocrine tumours (GEP NETs) patients treated with [177Lu]Lu-DOTATATE"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1389-3250","authenticated-orcid":false,"given":"Marco","family":"Maccauro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Cuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9116","authenticated-orcid":false,"given":"Matteo","family":"Bauckneht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3566-5179","authenticated-orcid":false,"given":"Matteo","family":"Bagnalasta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Mazzaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2311-1067","authenticated-orcid":false,"given":"Federica","family":"Scalorbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Argiroffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3923-1151","authenticated-orcid":false,"given":"Margarita","family":"Kirienko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Lorenzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Aliberti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pusceddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calareso","family":"Giuseppina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Matteo","family":"Garanzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Seregni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0634-013X","authenticated-orcid":false,"given":"Carlo","family":"Chiesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"issue":"35","key":"6863_CR1","doi-asserted-by":"publisher","first-page":"5377","DOI":"10.3748\/wjg.14.5377","volume":"14","author":"S Massironi","year":"2008","unstructured":"Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14(35):5377\u201384.","journal-title":"World J Gastroenterol"},{"issue":"10","key":"6863_CR2","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, Shih T, Yao JC. Trends in the incidence, Prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342.","journal-title":"JAMA Oncol"},{"issue":"2","key":"6863_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O\u2019Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J. NETTER-1 trial investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"key":"6863_CR4","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"issue":"5","key":"6863_CR5","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00259-013-2677-3","volume":"41","author":"S Ezziddin","year":"2014","unstructured":"Ezziddin S, Khalaf F, Vanezi M, Haslerud T, Mayer K, Al Zreiqat A, Willinek W, Biersack HJ, Sabet A. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1\/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41(5):925\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6863_CR6","doi-asserted-by":"crossref","unstructured":"Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, Borbath I, Cwikla J, Toumpanakis C, Kaltsas G, Davies P, H\u00f6rsch D, Tiensuu Janson E, Ramage J; participants. Antibes Consensus Conference, \u201cENETS consensus guidelines for the standards of care in neuroendocrine neoplasia: Peptide receptor radionuclide therapy with radiolabeled somatostatin analogues. Neuroendocrinology.\u00a02017;105(3):295-309","DOI":"10.1159\/000475526"},{"key":"6863_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00259-023-06420-z","volume":"51","author":"L Bodei","year":"2023","unstructured":"Bodei L, Michael Tuttle R, Grewal RK, Mauguen A, Augensen F, Abusamra M, Mahajan S, Jayaprakasam VS, Osborne JR, Haque S, Wong BZY, Ghossein RA, Fagin J, Sch\u04e7der H, Ho A, Humm JL, Larson SM. Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs. Eur J Nucl Med Mol Imaging. 2023;51:325\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6863_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2967\/jnumed.114.148437","volume":"56","author":"E Ilan","year":"2015","unstructured":"Ilan E, Sandstr\u00f6m M, Wassberg C, Sundin A, Garske-Rom\u00e1n U, Eriksson B, Granberg D, Lubberink M. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE. J Nucl Med. 2015;56(2):177\u201382.","journal-title":"J Nucl Med"},{"issue":"12","key":"6863_CR9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1007\/s00259-013-2504-x","volume":"40","author":"R Kashyap","year":"2013","unstructured":"Kashyap R, Jackson P, Hofman MS, Eu P, Beauregard JM, Zannino D, Hicks RJ. Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion. Eur J Nucl Med Mol Imaging. 2013;40(12):1853\u201360.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7\u20138","key":"6863_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1159\/000504001","volume":"110","author":"U Jahn","year":"2020","unstructured":"Jahn U, Ilan E, Sandstr\u00f6m M, Garske-Rom\u00e1n U, Lubberink M, Sundin A. 177Lu-DOTATATE peptide receptor radionuclide therapy: Dose response in small intestinal neuroendocrine tumors. Neuroendocrinology. 2020;110(7\u20138):662\u201370.","journal-title":"Neuroendocrinology"},{"issue":"1","key":"6863_CR11","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1038\/s41598-023-28977-3","volume":"13","author":"F Scalorbi","year":"2023","unstructured":"Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, Pusceddu S, Garanzini EM, Centonze G, Kirienko M, Seregni E, Milione M, Maccauro M. Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Sci Rep. 2023;13(1):1759.","journal-title":"Sci Rep"},{"issue":"9","key":"6863_CR12","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundl\u00f6v","year":"2017","unstructured":"Sundl\u00f6v A, Sj\u00f6green-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, Tennvall J. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"6863_CR13","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1007\/s00259-022-05786-w","volume":"49","author":"A Sundl\u00f6v","year":"2022","unstructured":"Sundl\u00f6v A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging. 2022;49(11):3830\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6863_CR14","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"6863_CR15","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","volume":"45","author":"U Garske-Rom\u00e1n","year":"2018","unstructured":"Garske-Rom\u00e1n U, Sandstr\u00f6m M, Fr\u00f6ss Baron K, Lundin L, Hellman P, Welin S, Johansson S, Khan T, Lundqvist H, Eriksson B, Sundin A, Granberg D. D. Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. Eur J Nucl Med Mol Imaging. 2018;45(6):970\u201388.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6863_CR16","doi-asserted-by":"publisher","unstructured":"Sj\u00f6green-Gleisner K, Flux G, Bacher K, Chiesa C, de Nijs R, Kagadis GC, Lima T, Georgosopoulou ML, Gabi\u00f1a PM, Nekolla S, Peters S, Santos J, Sattler B, Stokke C, Tran-Gia J, Gilligan P, Bardi\u00e8s M. EFOMP policy statement NO 19 Dosimetry in nuclear medicine therapy - Molecular radiotherapy. Phys Med.https:\/\/doi.org\/10.1016\/j.ejmp.2023.103166","DOI":"10.1016\/j.ejmp.2023.103166"},{"issue":"15","key":"6863_CR17","doi-asserted-by":"publisher","first-page":"8326","DOI":"10.3390\/ijms22158326","volume":"22","author":"JF Walrand","year":"2021","unstructured":"Walrand JF, Renal S. and red marrow dosimetry in peptide receptor radionuclide therapy: 20 years of history and ahead. Int J Mol Sci. 2021;22(15):8326.","journal-title":"Int J Mol Sci"},{"issue":"4 Suppl","key":"6863_CR18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1002\/cncr.24796","volume":"116","author":"M Garkavij","year":"2010","unstructured":"Garkavij M, Nickel M, Sj\u00f6green-Gleisner K, Ljungberg M, Ohlsson T, Wing\u00e5rdh K, Strand SE, Tennvall J. 177Lu-[DOTA0, Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084\u201392.","journal-title":"Cancer"},{"key":"6863_CR19","unstructured":"Editorial Board WHO. Digestive System Tumours, 5th ed., vol. 1, Lyon: International Agency for Research on Cancer, 2019."},{"key":"6863_CR20","unstructured":"European Medicine Agency, \u201cLutathera,\u201d [Online]. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera#product-details."},{"issue":"2","key":"6863_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer."},{"issue":"2","key":"6863_CR22","first-page":"119","volume":"52","author":"A Agresti","year":"1998","unstructured":"Agresti A, Coull BA. Approximate is better than \u201cexact\u201d for internal estimation of binomial proportions. Am Stat. 1998;52(2):119\u201326.","journal-title":"Am Stat"},{"issue":"4","key":"6863_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1120\/jacmp.v6i4.2142","volume":"6","author":"PH Halvorsen","year":"2005","unstructured":"Halvorsen PH, Das IJ, Fraser M, Freedman DJ, Rice RE 3rd, Ibbott GS, Parsai EI, Robin TT Jr. Thomadsen BR american association of physicists in medicine, \u201cAAPM task group 103 report on peer review in clinical radiation oncology physics.\u201d J Appl Clin Med Phys. 2005;6(4):50\u201364.","journal-title":"J Appl Clin Med Phys"},{"issue":"11","key":"6863_CR24","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00259-017-3707-3","volume":"44","author":"C Chiesa","year":"2017","unstructured":"Chiesa C, Sjogreen Gleisner K, Flux G, Gear J, Walrand S, Bacher K, Eberlein U, Visser EP, Chouin N, Ljungberg M, Bardi\u00e8s M, Lassmann M, Strigari L, Konijnenberg MW. The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2017;44(11):1783\u20136.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6863_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00259-013-2578-5","volume":"41","author":"E Seregni","year":"2014","unstructured":"Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, De Braud F, Buzzoni R, Milione M, Lorenzoni A, Bogni A, Coliva A, Lo Vullo S, Bombardieri E. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. Eur J Nucl Med Mol Imaging. 2014;41(2):223\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"6863_CR26","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","volume":"46","author":"M Del Prete","year":"2019","unstructured":"Del Prete M, Buteau FA, Arsenault F, Saighi N, Bouchard LO, Beaulieu A, Beauregard JM. Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging. 2019;46(3):728\u201342.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"6863_CR27","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.2967\/jnumed.123.266991","volume":"65","author":"CF Warfvinge","year":"2024","unstructured":"Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, \u00c5kesson A, Wieslander E, Sundl\u00f6v A, Sj\u00f6green GK. Relationship between absorbed dose and response in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE. J Nucl Med. 2024;65(5):1070\u20135.","journal-title":"J Nucl Med"},{"issue":"6","key":"6863_CR28","first-page":"515","volume":"56","author":"L Bianchi","year":"2012","unstructured":"Bianchi L, Baroli A, Lomuscio G, Pedrazzini L, Pepe A, Pozzi L, Chiesa C. Dosimetry in the therapy of metastatic differentiated thyroid cancer administering high 131I activity: the experience of Busto Arsizio Hospital (Italy). Q J Nucl Med Mol Imaging. 2012;56(6):515\u201321.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"13","key":"6863_CR29","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.1007\/s00259-020-04845-4","volume":"47","author":"C Chiesa","year":"2020","unstructured":"Chiesa C, Mira M, Bhoori S, Bormolini G, Maccauro M, Spreafico C, Cascella T, Cavallo A, De Nile MC, Mazzaglia S, Capozza A, Tagliabue G, Brusa A, Marchian\u00f2 A, Seregni E, Mazzaferro V. Radioembolization of hepatocarcinoma with 90Y glass microspheres: treatment optimization using the dose-toxicity relationship. Eur J Nucl Med Mol Imaging. 2020;47(13):3018\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"6863_CR30","doi-asserted-by":"publisher","first-page":"236","DOI":"10.2967\/jnumed.123.265987","volume":"65","author":"M Mileva","year":"2024","unstructured":"Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, Danieli R, Deleporte A, Picchia S, Stathopoulos K, Jungels C, Vanderlinden B, Paesmans M, Ameye L, Critchi G, Taraji-Schiltz L, Velghe C, Wimana Z, Bali M, Hendlisz A, Flamen P, Karfis I. Prediction of 177Lu-DOTATATE PRRT Outcome using multimodality imaging in patients with gastroenteropancreatic neuroendocrine tumors: Results from a prospective phase II LUMEN Study. J Nucl Med. 2024;65(2):236\u201344.","journal-title":"J Nucl Med"},{"issue":"6","key":"6863_CR31","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2967\/jnumed.123.267023","volume":"65","author":"K Hebert","year":"2024","unstructured":"Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Ass\u00e9nat E, Fersing C, G\u00e9libert P, Pouget JP, Bardi\u00e8s M, Kotzki PO, Deshayes E. Absorbed dose-response relationship in patients with gastroenteropancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTATATE: One step closer to personalized medicine. J Nucl Med. 2024;65(6):923\u201330.","journal-title":"J Nucl Med"},{"issue":"2","key":"6863_CR32","first-page":"205","volume":"55","author":"L Strigari","year":"2011","unstructured":"Strigari L, Benassi M, Chiesa C, Cremonesi M, Bodei L, D\u2019Andrea M. Dosimetry in nuclear medicine therapy: radiobiology application and results. Q J Nucl Med Mol Imaging. 2011;55(2):205\u201321.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"6","key":"6863_CR33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s00259-023-06112-8","volume":"50","author":"V Pirozzi Palmese","year":"2023","unstructured":"Pirozzi Palmese V, D\u2019Ambrosio L, Di Gennaro F, Maisto C, de Marino R, Morisco A, Coluccia S, Di Gennaro P, De Lauro F, Raddi M, Gaballo P, Tafuto S, Celentano E, Lastoria S. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice. Eur J Nucl Med Mol Imaging. 2023;50(6):1753\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"6863_CR34","doi-asserted-by":"publisher","first-page":"75","DOI":"10.2967\/jnumed.117.193706","volume":"59","author":"H H\u00e4nscheid","year":"2018","unstructured":"H\u00e4nscheid H, Lapa C, Buck AK, Lassmann M, Werner RA. Dose mapping after endoradiotherapy with 177Lu-DOTATATE\/DOTATOC by a Single Measurement After 4 Days. J Nucl Med. 2018;59(1):75\u201381.","journal-title":"J Nucl Med"},{"issue":"1","key":"6863_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40658-018-0210-2","volume":"5","author":"A Sundl\u00f6v","year":"2018","unstructured":"Sundl\u00f6v A, Gustafsson J, Brolin G, Mortensen N, Hermann R, Bernhardt P, Svensson J, Ljungberg M, Tennvall J, Sj\u00f6green Gleisner K. Feasibility of simplifying renal dosimetry in 177Lu peptide receptor radionuclide therapy. EJNMMI Phys. 2018;5(1):12.","journal-title":"EJNMMI Phys"},{"issue":"9\u201310","key":"6863_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/0284186X.2016.1182642","volume":"55","author":"J Heikkonen","year":"2016","unstructured":"Heikkonen J, M\u00e4enp\u00e4\u00e4 H, Hippel\u00e4inen E, Reijonen V, Tenhunen M. Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment. Acta Oncol. 2016;55(9\u201310):1069\u201376.","journal-title":"Acta Oncol"},{"issue":"13","key":"6863_CR37","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1007\/s00259-018-4136-7","volume":"45","author":"JI Gear","year":"2018","unstructured":"Gear JI, Cox MG, Gustafsson J, Gleisner KS, Murray I, Glatting G, Konijnenberg M, Flux GD. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging. 2018;45(13):2456\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"}],"updated-by":[{"DOI":"10.1007\/s00259-025-07378-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000}}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06863-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06863-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T23:08:54Z","timestamp":1749164934000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06863-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["6863"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06863-y","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"19 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00259-025-07378-w","URL":"https:\/\/doi.org\/10.1007\/s00259-025-07378-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted following the Declaration of Helsinki and approved by the local ethical committee (protocol name & number: LUTADOSE, INT 28\/20).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent at the time of PRRT.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Matteo Bauckneht reports personal fees from AAA and General Electric Healthcare outside the submitted work.Federica Scalorbi declares personal fees from AAA outside the submitted work.Carlo Chiesa received a fee as speaker at an online meeting by AAA.Marco Maccauro was supported by AAA for congress fee and he received an honorarium as consultant.The other authors do not report any conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}